b'<?xml version="1.0" ?>\n<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">\n<PubmedArticleSet>\n<PubmedArticle>\n    <MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM">\n        <PMID Version="1">29774135</PMID>\n        <DateRevised>\n            <Year>2019</Year>\n            <Month>11</Month>\n            <Day>20</Day>\n        </DateRevised>\n        <Article PubModel="Electronic-eCollection">\n            <Journal>\n                <ISSN IssnType="Electronic">1949-2553</ISSN>\n                <JournalIssue CitedMedium="Internet">\n                    <Volume>9</Volume>\n                    <Issue>31</Issue>\n                    <PubDate>\n                        <Year>2018</Year>\n                        <Month>Apr</Month>\n                        <Day>24</Day>\n                    </PubDate>\n                </JournalIssue>\n                <Title>Oncotarget</Title>\n                <ISOAbbreviation>Oncotarget</ISOAbbreviation>\n            </Journal>\n            <ArticleTitle>Vemurafenib in Langerhans cell histiocytosis: report of a pediatric patient and review of the literature.</ArticleTitle>\n            <Pagination>\n                <MedlinePgn>22236-22240</MedlinePgn>\n            </Pagination>\n            <ELocationID EIdType="doi" ValidYN="Y">10.18632/oncotarget.25277</ELocationID>\n            <Abstract>\n                <AbstractText>Selective BRAF inhibitors such as vemurafenib have become a treatment option in patients with Langerhans cell Histiocytosis (LCH). To date, only 14 patients receiving vemurafenib for LCH have been reported. Although vemurafenib can stabilize the clinical condition of these patients, it does not seem to cure the patients, and it is unknown, when and how to stop vemurafenib treatment. We present a girl with severe multisystem LCH who responded only to vemurafenib. After 8 months of treatment, vemurafenib was tapered and replaced by prednisone and vinblastine, a strategy which has not been described to date. Despite chemotherapy, early relapse occurred, but remission was achieved by re-institution of vemurafenib. Further investigation needs to address the optimal duration of vemurafenib therapy in LCH and whether and which chemotherapeutic regimen may prevent disease relapse after cessation of vemurafenib.</AbstractText>\n            </Abstract>\n            <AuthorList CompleteYN="Y">\n                <Author ValidYN="Y">\n                    <LastName>Heisig</LastName>\n                    <ForeName>Anne</ForeName>\n                    <Initials>A</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Division of Pediatric Hematology and Oncology, Hospital for Children and Adolescents, Johann Wolfgang Goethe-University, Frankfurt, Germany.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>S\xc3\xb6rensen</LastName>\n                    <ForeName>Jan</ForeName>\n                    <Initials>J</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Division of Stem Cell Transplantation and Immunology, Hospital for Children and Adolescents, Johann Wolfgang Goethe-University, Frankfurt, Germany.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Zimmermann</LastName>\n                    <ForeName>Stefanie-Yvonne</ForeName>\n                    <Initials>SY</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Division of Pediatric Hematology and Oncology, Hospital for Children and Adolescents, Johann Wolfgang Goethe-University, Frankfurt, Germany.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Sch\xc3\xb6ning</LastName>\n                    <ForeName>Stefan</ForeName>\n                    <Initials>S</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Division of Pediatric Hematology and Oncology, Hospital for Children and Adolescents, Johann Wolfgang Goethe-University, Frankfurt, Germany.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Schwabe</LastName>\n                    <ForeName>Dirk</ForeName>\n                    <Initials>D</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Division of Pediatric Hematology and Oncology, Hospital for Children and Adolescents, Johann Wolfgang Goethe-University, Frankfurt, Germany.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Kvasnicka</LastName>\n                    <ForeName>Hans-Michael</ForeName>\n                    <Initials>HM</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Institute of Pathology, Johann Wolfgang Goethe-University, Frankfurt, Germany.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Schwentner</LastName>\n                    <ForeName>Raphaela</ForeName>\n                    <Initials>R</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>St. Anna Kinderspital, Vienna, Austria.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Hutter</LastName>\n                    <ForeName>Caroline</ForeName>\n                    <Initials>C</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>St. Anna Kinderspital, Vienna, Austria.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Lehrnbecher</LastName>\n                    <ForeName>Thomas</ForeName>\n                    <Initials>T</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Division of Pediatric Hematology and Oncology, Hospital for Children and Adolescents, Johann Wolfgang Goethe-University, Frankfurt, Germany.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n            </AuthorList>\n            <Language>eng</Language>\n            <PublicationTypeList>\n                <PublicationType UI="D016428">Journal Article</PublicationType>\n            </PublicationTypeList>\n            <ArticleDate DateType="Electronic">\n                <Year>2018</Year>\n                <Month>04</Month>\n                <Day>24</Day>\n            </ArticleDate>\n        </Article>\n        <MedlineJournalInfo>\n            <Country>United States</Country>\n            <MedlineTA>Oncotarget</MedlineTA>\n            <NlmUniqueID>101532965</NlmUniqueID>\n            <ISSNLinking>1949-2553</ISSNLinking>\n        </MedlineJournalInfo>\n        <KeywordList Owner="NOTNLM">\n            <Keyword MajorTopicYN="N">BRAF</Keyword>\n            <Keyword MajorTopicYN="N">LCH</Keyword>\n            <Keyword MajorTopicYN="N">Langerhans cell histiocytosis</Keyword>\n            <Keyword MajorTopicYN="N">child</Keyword>\n            <Keyword MajorTopicYN="N">vemurafenib</Keyword>\n        </KeywordList>\n        <CoiStatement>CONFLICTS OF INTEREST The authors of this manuscript have no conflicts of interest to declare.</CoiStatement>\n    </MedlineCitation>\n    <PubmedData>\n        <History>\n            <PubMedPubDate PubStatus="received">\n                <Year>2018</Year>\n                <Month>03</Month>\n                <Day>12</Day>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="accepted">\n                <Year>2018</Year>\n                <Month>04</Month>\n                <Day>06</Day>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="entrez">\n                <Year>2018</Year>\n                <Month>5</Month>\n                <Day>19</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="pubmed">\n                <Year>2018</Year>\n                <Month>5</Month>\n                <Day>19</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="medline">\n                <Year>2018</Year>\n                <Month>5</Month>\n                <Day>19</Day>\n                <Hour>6</Hour>\n                <Minute>1</Minute>\n            </PubMedPubDate>\n        </History>\n        <PublicationStatus>epublish</PublicationStatus>\n        <ArticleIdList>\n            <ArticleId IdType="pubmed">29774135</ArticleId>\n            <ArticleId IdType="doi">10.18632/oncotarget.25277</ArticleId>\n            <ArticleId IdType="pii">25277</ArticleId>\n            <ArticleId IdType="pmc">PMC5955145</ArticleId>\n        </ArticleIdList>\n        <ReferenceList>\n            <Reference>\n                <Citation>Blood. 2010 Sep 16;116(11):1919-23</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">20519626</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>J Exp Med. 2014 Apr 7;211(4):669-83</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">24638167</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Blood Adv. 2017 Feb 2;1(6):352-356</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">29296950</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Hematology Am Soc Hematol Educ Program. 2014 Dec 5;2014(1):244-9</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">25696862</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>J Am Acad Dermatol. 2014 Sep;71(3):e97-9</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">25128147</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Pediatr Blood Cancer. 2004 Dec;43(7):770-6</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">15390280</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Pediatr Blood Cancer. 2016 Oct;63(10 ):1704-12</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">27314817</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>JAMA Oncol. 2018 Mar 1;4(3):384-388</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">29188284</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Eur J Cancer. 2017 Jul;79:176-184</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">28501764</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>JAMA Oncol. 2015 Sep;1(6):836-8</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">26180941</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>J Clin Oncol. 2016 Sep 1;34(25):3023-30</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">27382093</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Hematol Oncol Clin North Am. 1998 Apr;12(2):385-406</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">9561908</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>J Natl Compr Canc Netw. 2015 Jun;13(6):715-8</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">26085387</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Br J Haematol. 2017 Aug;178(3):457-467</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">28444728</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Oncotarget. 2014 Jun 30;5(12):4060-70</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">24938183</ArticleId>\n                </ArticleIdList>\n            </Reference>\n        </ReferenceList>\n    </PubmedData>\n</PubmedArticle>\n\n</PubmedArticleSet>'